Sign in to continue:

Sunday, February 15th, 2026

Genting Bhd (GENT MK) 2025 Analysis: Earnings Upgrade, RWNYC Upside & Target Price Raised to MYR4.24 | Maybank IBG Report Summary

Broker Name: Maybank Investment Bank Berhad
Date of Report: November 28, 2025
Excerpt from Maybank Investment Bank Berhad report.
Report Summary:

  • Maybank maintains a BUY rating on Genting Bhd (GENT MK), raising its target price to MYR4.24, citing stronger-than-expected gaming revenue at Resorts World Genting and higher projected earnings for FY25-27.
  • The report highlights key upcoming catalysts: Genting Malaysia’s bid for a New York commercial casino license (decision expected December 1, 2025) and potential privatisation of Genting Malaysia, which could significantly boost Genting Bhd’s earnings and valuation.
  • Genting’s diversified business spans casinos, plantations, property, biotechnology, and energy, but its ESG score was cut to 45/100 due to governance and sustainability concerns.
  • Financial metrics show steady revenue growth, EBITDA resilience, and manageable net gearing, with strategic focus on expanding high-margin mass market gaming and operational efficiency.
  • Risks include regulatory changes in key markets, volatility in VIP gaming, exposure to commodity prices, and related party transactions.

Above is an excerpt from a report by Maybank Investment Bank Berhad. Clients of Maybank Investment Bank Berhad can be the first to access the full report from the Maybank IBG website: www.maybank.com/investment-banking

CapitaLand Ascott Trust: Bullish Reversal Signal Emerges in Singapore REIT Market

Comprehensive Analysis of Companies in CGS-CIMB’s January 7, 2025 Report Comprehensive Analysis of Companies in CGS-CIMB’s January 7, 2025 Report Broker: CGS-CIMB | Date: January 7, 2025 CapitaLand Ascott Trust: Bullish Bottoming Out? CapitaLand...

Shanghai Pharmaceuticals (601607.SS) Stock Analysis 2025: Buy Rating, Growth Prospects & Financial Review

OCBC Investment Research Report Date: 15 September 2025 Shanghai Pharmaceuticals: Navigating Industry Headwinds, Accelerating Innovation, and Securing Market Leadership Executive Summary Shanghai Pharmaceuticals Holding Co. Ltd. (SPH), one of China’s top three drug distributors...

Midea’s Hong Kong IPO Raises HKD 31 Billion Amid Strong Global Investor Demand

Date: 17 September 2024Broker Name: MIB Securities (Hong Kong) Ltd Successful Hong Kong IPO Midea completed a highly successful Initial Public Offering (IPO) in Hong Kong, raising approximately HKD 31 billion. The deal was...

   Ad